Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Absci Corporation - Common Stock (NQ: ABSI )

2.970 +0.070 (+2.41%)
Streaming Delayed Price Updated: 12:17 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Absci Corporation - Common Stock

< Previous 1 2 3 4 5 Next >
Cathie Wood-Led Ark Invest Roblox, Roku, UiPath As Markets Take A Dip
Ark Invest made significant trades on Friday, selling shares of RBLX, ROKU, PATH and buying shares of IBTA, PSNL, ABSI, and RXRX. 
Via Benzinga
What's going on in today's after hours session
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
Peering Into Absci's Recent Short Interest
Via Benzinga
Crude Oil Edges Lower; Abbott Laboratories Posts Weak Sales
Via Benzinga
Exposures Fossil Fuels
Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside
Needham initiated a Buy rating for Absci (ABSI), noting its AI-powered drug discovery platforms, strategic partnerships, and $9 price target. 
Via Benzinga
Absci Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)
Via Benzinga
Earnings Scheduled For November 12, 2024
Via Benzinga
Nasdaq Surges 1.5%; Procter & Gamble Posts Upbeat Earnings
Via Benzinga
Seagate Posts Upbeat Earnings, Joins Netflix, Travelers, Teledyne Technologies And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
Cathie Wood's Ark Invest Buys Into Defense And Energy Stocks Amid Trump's Inaugural Policies
Cathie Wood-led Ark Invest made significant trades involving ACCD, DE, NTLA, PATH, CCJ, OKLO, ILMN, ESLT, and ABSI. 
Via Benzinga
Topics Government
Exposures Political
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
AAR Posts Upbeat Results, Joins AngioDynamics, eBay, Cal-Maine Foods And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Absci Stock Jumps As AMD Invests $20M To Boost AI Drug Discovery
Absci shares are rising after announcing a strategic collaboration with Advanced Micro Devices Inc. The partnership will enhance Absci's AI drug discovery capabilities using AMD Instinct accelerators... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Why DBV Technologies Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket
Via Benzinga
United Natural Foods Posts Upbeat Results, Joins Alphabet, Ollie's Bargain, MoneyLion And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 which should result in as many as 50 novel therapies being brought to market by then and generate annual... 
Via Talk Markets
AI-Focused Drug Discovery Stocks Portfolio -8% W/e Sept 6th
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 and should result in as many as 50 novel therapies being brought to market by then and generate annual... 
Via Talk Markets
Our AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone!
The August ISM manufacturing index reported on Tuesday that figures came in below consensus expectation. That raised fears about the strength of the economy, driving down our Our AI-Focused Drug... 
Via Talk Markets
Topics Economy
Exposures Economy
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The popular growth investor keeps adding to some of her favorite falling stocks. 
Via The Motley Fool
Our AI-Focused Drug Discovery Stocks Portfolio Was Up Almost 7% Last Week
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030. 
Via Talk Markets
ABSI Stock Earnings: Absci Misses EPS, Misses Revenue for Q2 2024
ABSI stock results show that Absci missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
AI-Focused Drug Discovery Stocks Portfolio Hit Hard: Down 14% MTD
The AI-powered drug discovery process is expected to grow by a 30% CAGR between now and 2030 which should result in approximately 50 novel therapies and generate annual sales in excess of $50 billion... 
Via Talk Markets
AI-Focused Drug Discovery Stocks Portfolio Up 7% Last Week; Up 19% MTD
The AI-powered drug discovery process is expected to grow by a CAGR of 30% by 2030. 
Via Talk Markets
Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average,... 
Via Talk Markets
Corning Increases Sales Forecast, Joins Morphic Holding, Lucid Group And Other Big Stocks Moving Higher On Monday
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Clinical-Stage BioTech Drug Stocks Declined 13% In June
Our BioTech Drug Stocks Portfolio was DOWN 13.2% in June. Before proceeding read 
Via Talk Markets
Cathie Wood's Ark Invest Sells Coinbase Shares As Bitcoin Drops Below Key $62K Level
On Monday, Cathie Wood-led Ark Invest made some significant trades, with Coinbase Global Inc. (NASDAQ:COIN) taking the spotlight. This comes amidst a turbulent market scenario, particularly for... 
Via Benzinga
Largest Clinical-Stage BioTech Drug Stocks Declined 6%
Of the 10 clinical-stage AI-focused and psychedelic compound-based small cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, only 1 advanced this week. On average they... 
Via Talk Markets
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.